OTTAWA, CANADA--(Marketwire - Oct. 13, 2011) - Wi-LAN Inc. ("WiLAN" or the "Company") (TSX:WIN)(NASDAQ:WILN) today announced the Ontario Securities Commission (the "OSC") has granted WiLAN's request to cease trade the MOSAID Technologies Incorporated ("MOSAID") Shareholder Rights Plan ("Poison Pill").

The cease trade order of MOSAID's Poison Pill is effective on November 1, 2011 at 9:00 a.m. (Eastern time). MOSAID had requested in its submissions that either WiLAN's application be dismissed or that the Poison Pill remain in place until November 11, 2011. The OSC declined to grant either of these requests from MOSAID in its order.

Accordingly, WiLAN will extend its C$38 per share all-cash bid for MOSAID shares until 5:00 p.m. (Eastern time) on November 1, 2011.

WiLAN is extremely pleased that the OSC agreed to cease trade MOSAID's Poison Pill and that the cease trade order will take effect in little more than two weeks. The decision now affords MOSAID shareholders the opportunity to consider and accept WiLAN's Offer.

About WiLAN

WiLAN, founded in 1992, is a leading technology innovation and licensing company. WiLAN has licensed its intellectual property to over 250 companies worldwide. Inventions in our portfolio have been licensed by companies that manufacture or sell a wide range of communication and consumer electronics products including 3G and 4G handsets, Wi-Fi-enabled laptops, Wi-Fi and broadband routers, xDSL infrastructure equipment, cellular base stations and digital television receivers. WiLAN has a large and growing portfolio of more than 1400 issued or pending patents. For more information: [ www.wilan.com ].

Forward-looking Information

This news release contains forward-looking statements and forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other United States and Canadian securities laws, including statements relating to WiLAN, WiLAN's formal offer to acquire all of the outstanding common shares of MOSAID (together with associated rights issued and outstanding under MOSAID's shareholder rights plan) (the "Offer") and any anticipated benefits to WiLAN resulting from the proposed acquisition of MOSAID. The phrase "will extend" and similar terms and phrases are intended to identify these forward-looking statements. Forward-looking statements and forward-looking information are based on estimates and assumptions made by WiLAN in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that WiLAN believes are appropriate in the circumstances.

Many factors could cause WiLAN's actual performance or achievements to differ materially from those expressed or implied by the forward-looking statements or forward-looking information. Such factors include, without limitation: (1) the risks described in WiLAN's August 3, 2011 management's discussion and analysis of financial condition and results of operations relating to its 3 and 6 months ended June 30, 2011 (the "MD&A") starting at page 29 of the MD&A; (2) the risks described in WiLAN's March 1, 2011 annual information form for the year ended December 31, 2011 (the "AIF") starting at page 13 of the AIF; and (3) the risks described below relating to the acquisition of MOSAID pursuant to the Offer as more fully discussed in WiLAN's September 2, 2011 final short-form prospectus relating to its offering of 6.00% extendible convertible unsecured subordinated debentures (the "Final Prospectus") starting at page 30 of the Final Prospectus:

1. WiLAN has not verified the reliability of any public information regarding MOSAID including any information included in the Final Prospectus;

2. the Offer is conditional upon, among other things, the receipt of consents and approvals from governments that could delay completion of the Offer or impose conditions that could result in an adverse effect on WiLAN's business or financial condition;

3. change of control or similar provisions in MOSAID's agreements triggered upon any acquisition of MOSAID may lead to adverse consequences;

4. any integration of WiLAN and MOSAID may not occur as anticipated;

5. WiLAN may be subject to significant capital requirements and operating risks associated with its expanded operations and its expanded portfolio of growth projects;

6. the proposed combination of WiLAN and MOSAID may not be successfully completed without the possibility of holders of MOSAID common shares exercising dissent and appraisal rights in connection with certain statutory transactions;

7. WiLAN may not realize the benefits of the combined company's new patent licensing programs;

8. WiLAN may be subject to significant operating risks associated with its expanded operations and its expanded portfolio of patents following the proposed acquisition of MOSAID;

9. WiLAN may assume significant unknown liabilities arising out of or related to MOSAID's business, operations or assets.

Copies of each of the MD&A and AIF may be obtained at [ www.sedar.com ] or [ www.sec.gov ] and copies of the Final Prospectus may be obtained at [ www.sedar.com ]. WiLAN recommends that readers review and consider all of these risk factors and notes that readers should not place undue reliance on any of WiLAN's forward-looking statements. WiLAN has no intention and undertakes no obligation to update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

All trademarks and brands mentioned in this release are the property of their respective owners.